LOGIN
ID
PW
MemberShip
2025-09-09 23:09
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Company
Eylea high-dosage PFS formulation wins nod in Korea
by
Whang, byung-woo
Aug 29, 2025 06:04am
Bayer Korea announced on August 28 that it has received domestic approval for 'Eylea PFS 8mg (aflibercept),' a pre-filled syringe formulation, from the Ministry of Food and Drug Safety (MFDS). The indication for 'Eylea PFS 8mg' has been approved the same as that for the existing Eylea vial formulation. Now, it can be administered more sim
Company
"200-day extension for the CMV preemptive therapy Prevymis"
by
Whang, byung-woo
Aug 28, 2025 06:10am
Prevymis (letermovir), a treatment for preventing cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients, is bringing in another paradigm shift as it has entered the '200-day extension criteria.' This drug's influence is expected to grow as the National Health Insurance (NHI) coverage period has been extend
Company
Kolon Pharma's active portfolio expansion¡¦new drug¡¤co-dev
by
Son, Hyung Min
Aug 28, 2025 06:10am
Kolon Pharma is increasing its efforts to secure competitiveness in immunology and oncology by combining new drug in-licensing with in-house R&D. Following the introduction of treatments for chronic obstructive pulmonary disease (COPD) and allergies, the company has recently secured a new drug for hypoparathyroidism. Kolon Pharma plans to contin
Company
New ADC drug introduced¡¦expands treatment options
by
Son, Hyung Min
Aug 28, 2025 06:09am
New global drugs are awaiting entry into Korea¡¯s antibody-drug conjugate (ADC) market one after another. Following Daiichi Sankyo Korea's application for domestic approval of the ADC anticancer drug ¡®Datroway,¡¯ AbbVie Korea is also proceeding with the approval process for its ovarian cancer-targeted ADC ¡®Elahere.¡¯ The industry anticipates t
Company
Jaypirca¡¯s reimbursement imminent in Korea
by
Eo, Yun-Ho
Aug 27, 2025 06:07am
The BTK inhibitor Jaypirca is likely to be listed for reimbursement soon. According to Dailypharm coverage, the National Health Insurance Service (NHIS) and Lilly Korea recently completed price negotiations for Jaypirca (pirtobrutinib), a treatment for relapsed or refractory mantle cell lymphoma (MCL). As a result, Jaypirca¡¯s reimburs
Company
Targeted therapies and antibody drugs enter clinical trials
by
Son, Hyung Min
Aug 27, 2025 06:07am
Korea¡¯s pharmaceutical and biotech industry is accelerating new drug development for pancreatic cancer, a cancer regarded as one of the most intractable cancers. Onconic Therapeutics, Prestige Biopharma, and Aptamer Sciences have each started clinical trials, making their bid into the field. The company plans to test the commercial viability of
Company
Co-promotion discussed for the diabetes drug Mounjaro
by
Kim, Jin-Gu
Aug 27, 2025 06:07am
The possibility of a co-promotion partnership between Eli Lilly and Korean pharmaceutical companies for 'Mounjaro,' the treatment of diabetes and obesity, continues to be discussed. While Lilly Korea officially maintains a 'direct sales' policy, it is reported that they are also conducting undiscloed discussions for potential partnerships.
Company
CKD aims at developing next-generation¡¤new anti-cancer drug
by
Son, Hyung Min
Aug 26, 2025 06:06am
Chong Kun Dang is speeding up investment in the new anti-cancer drug sector. The company aims to commercialize anti-cancer drugs by advancing its in-house pipelines for Antibody-Drug Conjugates (ADCs) and Cell and Gene Therapies (CGTs). Additionally, Chong Kun Dang is securing domestic rights for new drugs, including Chimeric Antigen Receptor T-
Company
Expanded indication for Kisqali in early breast cancer
by
Son, Hyung Min
Aug 26, 2025 06:05am
On August 22, Novartis Korea (CEO and President Byeong-jae Yoo) announced that its CDK 4/6 inhibitor, Kisqali, was approved for a new indication from the Ministry of Food and Drug Safety for use as an adjuvant therapy in patients with HR+ (hormone receptor-positive)/HER2- (human epidermal growth factor receptor 2-negative) Stage II and III e
Company
Will companies pass Korea due to Trump¡¯s drug price reform?
by
Moon, sung-ho
Aug 26, 2025 06:05am
Since Trump took office, the US has designated the pharmaceutical industry as its core strategic industry and is working to reshape the industry with the US at its center. The goal is to significantly lower drug prices in the U.S., the world's largest pharmaceutical market. However, the ¡°Most-Favored-Nation Pricing (MFN)¡± policy recently a
1
2
3
4
5
6
7
8
9
10
>